Transient transfection methods for clinical adeno-associated viral vector production.
about
Manufacturing of recombinant adeno-associated viral vectors for clinical trialsScalable downstream strategies for purification of recombinant adeno- associated virus vectors in light of the properties.Producing recombinant adeno-associated virus in foster cells: overcoming production limitations using a baculovirus-insect cell expression strategy.Scale-up and manufacturing of clinical-grade self-inactivating γ-retroviral vectors by transient transfectionAdeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them.Adeno-associated virus: a key to the human genome?Large-scale recombinant adeno-associated virus productionAAV vectors for cardiac gene transfer: experimental tools and clinical opportunities.Recombinant adeno-associated viral vector production and purification.Human galectin 3 binding protein interacts with recombinant adeno-associated virus type 6Progress and challenges in viral vector manufacturingAAV-mediated gene therapy for liver diseases: the prime candidate for clinical application?Downstream processing of cell culture-derived virus particles.Current status of haemophilia gene therapy.Cellular unfolded protein response against viruses used in gene therapyPeptide affinity reagents for AAV capsid recognition and purificationEfficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.Characteristics of Minimally Oversized Adeno-Associated Virus Vectors Encoding Human Factor VIII Generated Using Producer Cell Lines and Triple Transfection.Manufacturing of recombinant adeno-associated viruses using mammalian expression platforms.AAV2 production with optimized N/P ratio and PEI-mediated transfection results in low toxicity and high titer for in vitro and in vivo applications.Adeno-Associated Virus (AAV) as a Vector for Gene Therapy.Clearance and characterization of residual HSV DNA in recombinant adeno-associated virus produced by an HSV complementation system.Gene Delivery Approaches for Mesenchymal Stem Cell Therapy: Strategies to Increase Efficiency and Specificity.Extended gene expression by medium exchange and repeated transient transfection for recombinant protein production enhancement.Proteomics analysis of co-purifying cellular proteins associated with rAAV vectors.Advancements in the design and scalable production of viral gene transfer vectors.C-reactive protein (CRP) is essential for efficient systemic transduction of recombinant adeno-associated virus vector 1 (rAAV-1) and rAAV-6 in mice.A comparative study on nonviral genetic modifications in cord blood and bone marrow mesenchymal stem cells.Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale.Molecular design for recombinant adeno-associated virus (rAAV) vector production.Large-Scale Transient Transfection of Suspension Mammalian Cells for VLP Production.Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse.AAV-8 and AAV-9 Vectors Cooperate with Serum Proteins Differently Than AAV-1 and AAV-6
P2860
Q26750799-58127128-6128-40CB-80DF-D5687472EFFEQ33555259-A7D76A95-11FD-4268-818E-C1D821BDCF40Q33690975-1281E192-1626-4516-902A-EFB0F8E668F0Q34204409-1321E80E-BCB8-481C-A150-DFBE6C71681BQ34370111-9E119A5A-45F9-410F-AD57-10EBC9378940Q34459999-76162298-6D9A-4815-825C-4F0061DE8EDCQ34982857-0E2E957D-1C60-40FE-B73C-164CC6F84864Q35238264-9831D121-4D18-40B0-ACF7-BE1B7B363A50Q35819157-1C57F7C4-5752-4268-B9BB-FDFDAD8E7C2DQ36086772-17DA6078-DBE7-46E6-9458-4721809A822BQ36713761-C7060F50-ED8E-448D-9647-BF1AE251F7A0Q37825907-94EE6F51-4540-4E35-AF1F-3AAC98E51037Q37944322-9330B907-9FE2-4B41-9F7F-8B0FB5AB69BCQ38206852-2C45E872-F823-4D12-A2D4-1F6FC5685590Q38218111-24A9861A-A22F-4B31-B1A2-D0A7E697E752Q38335916-C7274A19-3CF4-49BD-9DEA-FCB15EB9D93CQ38676926-4DB03691-455F-445B-86ED-2331218ECCC7Q38717682-6C5A73A7-FB10-45B4-B2B4-8C7B15BEEFEEQ39126013-4EAAFAF3-DB7D-4D59-8C7F-8B61498987DCQ39136603-D666C8A7-8F84-40F4-B4EE-2A0A681245F4Q39409371-A96A296F-D23C-496E-B897-6631B60EEF3EQ39674124-F23E9DCD-A3CB-46FA-B0C5-FF211B841739Q40080450-EE549D72-9E71-402D-9740-182C35CBA10AQ41649944-401DDAA7-92F2-4675-8FC4-A860B0DE64C9Q41778815-E18CAAED-2A65-49DC-A67E-AF0F4494EFD5Q41931475-F142C14A-28A5-4418-BA83-0A3F3E711DF7Q42030992-338BA412-5547-4327-B64F-98965DC76B3CQ42322592-4915BB1E-BC1D-421E-8AAE-C773026B66F6Q42408230-3D3C59BD-8B35-472D-B0C3-F0C7A5C96E14Q45323804-146D4E33-3C3A-44F4-ACE5-D2E4FC1EEA8BQ50046042-FBE37121-CACD-4189-A550-D1DD02B1094AQ55471442-83EE8B5B-E166-495E-818A-F114945D5313Q58795206-1D061149-4FD9-473D-827C-D08DDCC63277
P2860
Transient transfection methods for clinical adeno-associated viral vector production.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Transient transfection methods for clinical adeno-associated viral vector production.
@en
Transient transfection methods for clinical adeno-associated viral vector production.
@nl
type
label
Transient transfection methods for clinical adeno-associated viral vector production.
@en
Transient transfection methods for clinical adeno-associated viral vector production.
@nl
prefLabel
Transient transfection methods for clinical adeno-associated viral vector production.
@en
Transient transfection methods for clinical adeno-associated viral vector production.
@nl
P2860
P356
P1433
P1476
Transient transfection methods for clinical adeno-associated viral vector production.
@en
P2093
J Fraser Wright
P2860
P304
P356
10.1089/HUM.2009.064
P577
2009-07-01T00:00:00Z